An Open Labeled, Noncomparative, Phase I Study to Evaluate the Safety and tolerability of a Fully Liquid Hexavalent DTwP-HepB-Hib-IPV Vaccine (Easysix, Panacea Biotec Ltd.) in Healthy Subjects 15 - 18 months of age.
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Hib-DTP-hepatitis B-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- Sponsors Panacea Biotec
- 23 Dec 2010 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India record.
- 20 Sep 2010 New trial record